John F Crowley bought stock once, on Jan 12, 2022
Executive Chair at Amicus Therapeutics, Inc., and 2 other companies
SEC CIK 0001400973 · Filings on SEC.gov ↗
John F Crowley's record
3 months after each buy, from the first price a copier could get.
1 buy has 3 months of prices so far. A record shows here at 3.
Companies
Every filing
115 filings since Oct 2017, newest first
Amicus Therapeutics, Inc.
Executive Chair
Amicus Therapeutics, Inc.
Executive Chair
Amicus Therapeutics, Inc.
Executive Chair
Amicus Therapeutics, Inc.
Executive Chair
Amicus Therapeutics, Inc.
Executive Chair
Amicus Therapeutics, Inc.
Executive Chair
Amicus Therapeutics, Inc.
Executive Chair
Amicus Therapeutics, Inc.
Executive Chair
Amicus Therapeutics, Inc.
Executive Chair
Amicus Therapeutics, Inc.
Executive Chair
Amicus Therapeutics, Inc.
Executive Chair
Amicus Therapeutics, Inc.
Executive Chair
Amicus Therapeutics, Inc.
Executive Chair
Amicus Therapeutics, Inc.
Executive Chair
Amicus Therapeutics, Inc.
Executive Chair
Amicus Therapeutics, Inc.
Executive Chair
Amicus Therapeutics, Inc.
Executive Chair
Amicus Therapeutics, Inc.
Executive Chair
Amicus Therapeutics, Inc.
Executive Chair
Amicus Therapeutics, Inc.
Executive Chair
Amicus Therapeutics, Inc.
Executive Chair
Amicus Therapeutics, Inc.
Executive Chair
Amicus Therapeutics, Inc.
Executive Chair
Amicus Therapeutics, Inc.
Executive Chair
Amicus Therapeutics, Inc.
Executive Chair
Amicus Therapeutics, Inc.
Executive Chair
Amicus Therapeutics, Inc.
Executive Chair
Amicus Therapeutics, Inc.
Executive Chair
Amicus Therapeutics, Inc.
Executive Chair
Amicus Therapeutics, Inc.
Executive Chair
Amicus Therapeutics, Inc.
Executive Chair
Amicus Therapeutics, Inc.
Executive Chair
Amicus Therapeutics, Inc.
Executive Chair
Amicus Therapeutics, Inc.
Executive Chair
Amicus Therapeutics, Inc.
Executive Chair
Amicus Therapeutics, Inc.
Executive Chair
Amicus Therapeutics, Inc.
Executive Chair
Amicus Therapeutics, Inc.
Executive Chair
Amicus Therapeutics, Inc.
Executive Chair
Amicus Therapeutics, Inc.
Chair and CEO
Amicus Therapeutics, Inc.
Chair and CEO
Amicus Therapeutics, Inc.
Chair and CEO
Amicus Therapeutics, Inc.
Chair and CEO
Amicus Therapeutics, Inc.
Chair and CEO
Amicus Therapeutics, Inc.
Chair and CEO
Amicus Therapeutics, Inc.
Chair and CEO
Entrada Therapeutics, Inc.
Director
Amicus Therapeutics, Inc.
Chair and CEO
Amicus Therapeutics, Inc.
Chair and CEO
Amicus Therapeutics, Inc.
Chair and CEO
About John F Crowley
John F. Crowley is a biotechnology executive and patient advocate best known as the founder, longtime chairman, and CEO of Amicus Therapeutics, Inc., where he has served as Executive Chairman/Executive Chair of the Board after leading the company’s growth into a global biopharmaceutical firm focused on rare genetic diseases.( A co‑founder of Novazyme Pharmaceuticals—later acquired by Genzyme—Crowley has spent decades in biotech, driven in part by the 1998 diagnosis of two of his children with Pompe disease, which led him to build companies developing life‑saving therapies for rare disorders.( He became a director at Amicus in 2004 and its first CEO in 2005, overseeing expansion from a small start‑up to hundreds of employees across more than two dozen countries and a multibillion‑dollar market valuation.(
Crowley is currently President and CEO of the Biotechnology Innovation Organization (BIO), the largest biotechnology advocacy organization in the world, following many years as a BIO board member.( His broader career includes senior leadership roles at Genzyme after the sale of Novazyme, founding Orexigen Therapeutics, and service as National Chairman of the Make‑A‑Wish Foundation of America.( A U.S. Navy Reserve veteran who served with Joint Special Operations Command and other elite units, Crowley has also been recognized through profiles in major media and as the inspiration for the film Extraordinary Measures.( He attended the U.S. Naval Academy and earned a B.S. in Foreign Service from Georgetown University, a J.D. from Notre Dame Law School, and an M.B.A. from Harvard Business School.(
Written by Perplexity from public sources.
Filings come from SEC EDGAR. Not investment advice.